APLS Q3 2018 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$2B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$36M

Operating Income

-$36M

Net Income

-$36M

EPS (Diluted)

$-0.64

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$239M

Total Liabilities

$43M

Stockholders' Equity

$196M

Cash & Equivalents

$221M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$36M	-$12M	-209.0%
Operating Income	-$36M	-$12M	-209.0%
Net Income	-$36M	-$12M	-210.8%